Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

NCT05317819 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma

Interventions

DRUG: ADI-PEG20
OTHER: Placebo

Sponsor

Polaris Group